ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

HYPR Hyperfine Inc

0.8375
0.0375 (4.69%)
27 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Hyperfine Inc NASDAQ:HYPR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0375 4.69% 0.8375 0.812 0.9375 0.87 0.80 0.80 56,095 01:00:00

Hyperfine, Inc. to Present at the Jefferies Global Healthcare Conference

22/05/2024 9:05pm

Business Wire


Hyperfine (NASDAQ:HYPR)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more Hyperfine Charts.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced plans to present at the upcoming Jefferies Global Healthcare Conference, in New York, NY. Members of management are scheduled to present on Thursday, June 6, 2024, at 3:00 pm ET.

A live webcast of the event, as well as an archived recording will be available on the “Investors” section of the company’s website at: investors.hyperfine.io. The webcasts will be archived and available for replay for at least 90 days after the event.

For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io.

About Hyperfine, Inc. and the Swoop® Portable MR Imaging® System

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020 as a portable magnetic resonance brain imaging device for producing images that display the internal structure of the head where a full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system has been approved for brain imaging in several countries, including Canada and Australia, has UKCA certification in the United Kingdom, CE certification in the European Union, and is also available in New Zealand.

The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. Traditionally, access to costly, stationary, conventional MRI technology can be inconvenient or not available when needed most. With the portable, ultra-low-field Swoop® system, Hyperfine, Inc. is redefining the neuroimaging workflow by bringing brain imaging to the patient’s bedside. For more information, visit hyperfine.io.

Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

Investor Contact Webb Campbell Gilmartin Group LLC webb@gilmartinir.com

1 Year Hyperfine Chart

1 Year Hyperfine Chart

1 Month Hyperfine Chart

1 Month Hyperfine Chart

Your Recent History

Delayed Upgrade Clock